Ardelyx, Inc. (ARDX) Stock AnalysisARDXArdelyx, Inc.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Ardelyx Inc (ARDX) is not a good buy. The stock is trading at $3.28, significantly below its 200-day simple moving average of $5.574, indicating a bearish trend. Additionally, the RSI is at 31.853, suggesting that the stock is oversold but may continue to face downward pressure. The company is also dealing with negative catalysts, including a recent legal setback regarding Medicare coverage for its drug Xphozah, which could impact future revenues. The stock has seen a year-to-date decline of 46.67%, and hedge funds have increased selling by 129.11% over the last quarter, indicating a lack of confidence among institutional investors. The main risk is the ongoing class action lawsuit against the company, which could further affect its stock price.

7 analysts cover ARDX: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.86.